Breast Cancer
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
- Details
ClinicalTrials.gov ID:
NCT03725059
Diagnosis Type:
NA
USOR Number:
- Address
8196 Walnut Hill Lane, Suite 100
Dallas, TX 75231
P: (214) 345-7394